FRISCO, Texas--(BUSINESS WIRE)--Soleo Health, an innovative leader and national provider of complex specialty pharmacy services for treating rare- and ultra-rare diseases, announced today it has been named a limited distribution specialty pharmacy partner to dispense RYPLAZIM® (plasminogen, human-tvmh), manufactured by Kedrion Biopharma..

德克萨斯州弗里斯科——（商业新闻短讯）——Soleo Health是治疗罕见和超罕见疾病的复杂专业药房服务的创新领导者和国家供应商，今天宣布，它已被指定为有限分销专业药房合作伙伴，以分销Kedrion Biopharma生产的RYPLAZIM®（纤溶酶原，人类tvmh）。。

RYPLAZIM is the first and only Food & Drug Administration (FDA)-approved treatment for supporting the approximately 500 people in the U.S. affected by plasminogen deficiency type 1 (PLGD-1). Considered an ultra-rare disease, PLGD-1 leads to reduced plasminogen activity levels in the body, often resulting in fibrinous lesions on various organs.

RYPLAZIM是美国食品和药物管理局（FDA）批准的第一种也是唯一一种治疗方法，用于支持美国约500名受纤溶酶原缺乏症1型（PLGD-1）影响的患者。PLGD-1被认为是一种极为罕见的疾病，可导致体内纤溶酶原活性降低，通常会导致各种器官的纤维蛋白病变。

Approximately 81% of patients develop lesions on one or both eyes as their primary symptom; however, lesions can develop throughout the body, potentially on all organs with mucous membranes. Patients with PLGD-1 may require lifelong treatment..

大约81%的患者以单眼或双眼病变为主要症状；然而，病变可能在全身发展，可能在所有有粘膜的器官上发展。PLGD-1患者可能需要终身治疗。。

'We at Kedrion Biopharma appreciate our ongoing partnership with Soleo Health, especially with our latest specialty pharmaceutical, RYPLAZIM. We are confident that our continued collaboration will further improve the lives of patients suffering from PLGD-1 to ensure this essential medication reaches those who need it most,' asserted Bob Rossilli, chief commercial officer of Kedrion Biopharma..

“Kedrion Biopharma感谢我们与Soleo Health的持续合作，特别是与我们最新的专业制药公司RYPLAZIM的合作。Kedrion Biopharma首席商务官鲍勃·罗西利（BobRossilli）断言：“我们相信，我们的持续合作将进一步改善PLGD-1患者的生活，以确保这种基本药物能够惠及最需要的人。”。。

'We take pride in being among the few selected specialty pharmacy providers administering RYPLAZIM to PLGD-1 patients. Complex conditions like PLGD-1 require our clinical excellence and extensive knowledge to ensure patients receive appropriate access to treatment while simplifying their complex care.

“我们为自己是为数不多的为PLGD-1患者管理RYPLAZIM的精选专业药房供应商之一而感到骄傲。PLGD-1等复杂疾病需要我们卓越的临床表现和广泛的知识，以确保患者在简化复杂护理的同时获得适当的治疗。

We are thankful for our relationship with Kedrion and the opportunity to make a significant difference in these patients’ lives,' explained Drew Walk, chief executive officer of Soleo Health..

Soleo Health首席执行官德鲁·沃克（DrewWalk）解释说，我们感谢我们与凯德里恩（Kedrion）的关系，以及有机会为这些患者的生活带来重大改变。。

For more information about receiving RYPLAZIM therapy and services through Soleo Health, contact the Company at phone 844.547.8600 or fax 380.257.2419.

有关通过Soleo Health接受RYPLAZIM治疗和服务的更多信息，请致电844.547.8600或传真380.257.2419与该公司联系。

About Soleo Health

关于Soleo Health

Frisco, Texas-based Soleo Health is a leading national provider of complex specialty pharmacy services administered in the home or at alternate sites of care. Soleo Health’s interdisciplinary team comprises highly experienced clinical pharmacists, registered nurses, reimbursement specialists and patient care ambassadors collaborating with its referring partners..

总部位于德克萨斯州弗里斯科的Soleo Health是国内领先的复杂专业药房服务提供商，可在家中或其他护理场所管理。Soleo Health的跨学科团队由经验丰富的临床药剂师、注册护士、报销专家和与推荐合作伙伴合作的患者护理大使组成。。

The Company optimizes patient access solutions and delivers comprehensive services, leading to quantifiable clinical and economic value, resulting in positive patient experiences. Soleo Health has 26 pharmacy locations with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs and The Joint Commission.

该公司优化了患者接入解决方案并提供了全面的服务，从而产生了可量化的临床和经济价值，从而带来了积极的患者体验。Soleo Health在50个州拥有26家药房，拥有全国护理覆盖范围和药房许可证，并获得URAC、ACHC和联合委员会的认证，在罕见病和孤儿药方面取得了优异成绩。

Additionally, the Company operates more than 30 infusion centers throughout the U.S..

此外，该公司在美国各地运营着30多个输液中心。。

Visit www.soleohealth.com or connect with Soleo Health on LinkedIn, Facebook and X for more information.

有关更多信息，请访问www.soleohealth.com或在LinkedIn、Facebook和X上与Soleo Health联系。